Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Online information discrepancies regarding safety of medicine use during pregnancy and lactation: an IMI ConcePTION study.
Journal: Expert opinion on drug safety
Published: June 03, 2021
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 02, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 19, 2017
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Journal: The oncologist
Published: February 02, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 18, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Journal: The Lancet. Oncology
Published: September 03, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Journal: The Lancet. Oncology
Published: January 27, 2016
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: December 08, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026